Amgen
S&P 500
Nasdaq 100
Dow Jones
$461.26
-0.90%
Delayed · cached 15 min
Peer comparison
| Company | Price↕ | Market Cap↕ | P/E↕ | P/B↕ | ROE %↕ | ROCE %↕ | Div yield %↕ | Valuation |
|---|---|---|---|---|---|---|---|---|
| AbbVie | $ 286.00 | $505.40B | 49.65 | -85.14 | -71.20 | 16.42 | 2.40 | — |
| Amgen | $ 461.26 | $249.37B | 28.92 | 21.33 | 65.97 | 12.94 | 2.11 | Above FV |
| Gilead Sciences | $ 167.47 | $207.72B | 24.70 | 15.94 | 65.26 | 25.31 | 1.91 | Above FV |
| Vertex Pharmaceuticals | $ 530.76 | $134.53B | 35.60 | 7.22 | 19.52 | 17.71 | 0.00 | Above FV |
| Regeneron Pharmaceuticals | $ 973.36 | $100.69B | 21.25 | 2.91 | 13.45 | 8.94 | 0.38 | Above FV |
| Moderna | $ 228.44 | $91.20B | -31.47 | 13.48 | -41.74 | -34.25 | 0.00 | — |
| Biogen | $ 248.93 | $36.80B | 107.76 | 1.94 | 8.74 | 5.42 | 0.00 | Above FV |
| United Therapeutics | $ 601.32 | $25.79B | 21.32 | 4.01 | 20.85 | 22.41 | 0.00 | Above FV |
| Incyte | $ 117.59 | $23.97B | 61.24 | 4.25 | 22.80 | 26.24 | 0.00 | Above FV |
| Alnylam Pharmaceuticals, Inc. | $ 159.89 | $21.42B | 7.98 | 5.94 | 8.71 | 7.68 | 0.00 | Above FV |
| Insmed Incorporated | $ 104.44 | $22.91B | -16.27 | 31.54 | -181.14 | -77.58 | 0.00 | — |
| Exelixis | $ 72.31 | $17.64B | 20.96 | 9.65 | 42.67 | 41.38 | 0.00 | Above FV |
Price, market cap, P/E, P/B and dividend yield reflect the live quote (delayed, cached 15 min); ROE/ROCE from reported financials. The highlighted row is the current company. Click a column header to sort. Educational data only.
How to read the peer comparison
This table places the company beside others in the same industry on a few common measures. Comparison adds context that a single company's numbers cannot give on their own.
- Valuation multiples like P/E and P/B are most meaningful within the same industry, because different industries naturally trade at different levels. Comparing a company only to its peers is more useful than to the whole market.
- Return measures (ROE, ROCE) show how efficiently each company turns capital into profit. A company well ahead of or behind its peers here is worth understanding.
- No single column decides anything. A beginner reads the row across — valuation, returns, and size together — and treats the highlighted current company as one data point among its peers.
- Use the sortable headers to rank peers on any measure, but remember that "cheaper" or "higher" on one metric is a starting question, not an answer.
Educational only — not a recommendation to buy, sell, or hold any security.